First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Authors: Huilai Zhang,1 Ying Cheng,2 Haiyan Yang,3 Liling Zhang,4 Liqun Zou,5 Ye Guo,6 Junning Cao,7 Huiqiang Huang,8 Zhao Wang,9 Sha Huang,10 Zhiyu Liang,10 Jiaoyan Lyu,10 Yiqian Fang,10 Aileen Cohen,10 and Keshu Zhou11

Affiliations: 1Tianjin Medical University Cancer Institute & Hospital, Tianjin, China; 2Jilin Cancer Hospital, Changchun, China; 3The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; 4Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 5West China Hospital, Sichuan University, Chengdu, China; 6Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China; 7Fudan University Shanghai Cancer Center, Shanghai, China; 8Sun Yat-Sen University Cancer Center, Guangzhou, China; 9Beijing Friendship Hospital, Capital Medical University, Beijing, China; 10BeiGene (Shanghai) Co., Ltd. Shanghai, China, BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA; and 11Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

Introduction: Effective therapies for R/R DLBCL are limited in China, especially for patients (pts) who are ineligible for high-dose therapy/stem cell transplantation (HDT/SCT). Preclinical data suggest synergy of len and zanu, a potent and selective Bruton tyrosine kinase inhibitor approved for various B-cell malignancies (Guo et al. J Med Chem 2019). Here, we present the interim analysis of an ongoing phase 1, open-label, dose-escalation/expansion study of zanu + len in R/R DLBCL in China (NCT04436107).

Methods: Pts with R/R DLBCL ineligible for HDT/SCT with ≥1 prior line of adequate systemic therapy were enrolled. Dose escalation (part 1): Len 15 mg, 20 mg, or 25 mg orally once daily on days 1-21 of each 28-day cycle. Dose expansion (part 2): Len 25 mg. Zanu 160 mg was given orally twice daily continuously in parts 1 and 2. Primary endpoints were safety and recommended phase 2 dose (RP2D) of len (part 1) and overall response rate (ORR) by investigator based on Lugano classification (part 2). Interim analysis was performed when the 19th pt in part 2 completed first tumor assessment. Pts who received len 25 mg (RP2D) in parts 1 and 2 were analyzed separately.

Results: As of November 8, 2022, 46 pts were treated and included in the analysis (27 in part 1; 19 in part 2; 30 at RP2D). Median age was 60 years (range, 29-82), 83% had stage III-IV disease, 37% had refractory disease, 70% had non-germinal center B-cell (non-GCB)-like disease; and median number of prior systemic therapies was 1 (range, 1-5).

Median exposure to zanu and len was 3.9 months (range, 0.4-24.9), median follow-up was 6.6 months (range, 0.5-25.5). ORR was 46% overall (95% CI: 30.9, 61.0; complete response [CR]: 24%) and 57% at RP2D (95% CI: 37.4, 74.5; CR: 30%). At RP2D, ORR was 61% (95% CI: 38.5, 80.3; CR: 35%) for pts with non–GCB-like disease and 50.0% (95% CI: 11.8, 88.2; CR: 17%) for GCB. At
RP2D, median duration of response was not reached and 6-month event-free rate was 59% (95% CI: 23.8, 82.8). The 9-month progression-free survival rate was 37% (95% CI: 17.6, 57.4).

Overall, 46 (100%) pts experienced ≥1 treatment-emergent adverse event (TEAE). At RP2D, grade ≥3 TEAEs occurred in 60% of pts, most commonly neutrophil count decreased (43%), white blood cell count decreased (23%), and pneumonia (13%). One patient (2%) had febrile neutropenia (grade 3) but recovered within 2 days. TEAEs led to discontinuation of both len and zanu in 2 pts (cardiopulmonary failure unrelated to treatment [part 1, len 20 mg], pulmonary embolism [part 1, len 25 mg]) and discontinuation of len in 2 pts (platelet count decreased [part 1, len 20 mg], rash [part 2]). Two TEAEs leading to death were assessed as unrelated to treatment.

Conclusions: Zanu 160 mg + len 25 mg combination showed an acceptable safety profile with promising efficacy. Further evaluation of the combination in a larger sample size is planned in future analysis.